Multi-omics approach revealed Pro-osteogenic properties of Barrier to antointegration factor 1 (BANF1)
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA944255 | ENA |
REPOSITORIES: ENA
Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| SRR23851559.fastq.gz | Fastqsanger.gz | |||
| SRR23851560.fastq.gz | Fastqsanger.gz | |||
| SRR23851561.fastq.gz | Fastqsanger.gz | |||
| SRR23851562.fastq.gz | Fastqsanger.gz |
Items per page: 5 1 - 4 of 4 |
Similar Datasets
Project description:Growth, remodeling, adaptation and repair of bone is critically dependent on the ability of tissue resident progenitors to differentiate into and thereby renew parenchymal cells of the osteoblast, chondrocyte, and adipocyte lineage. We recently reported that the activation of osteoblast-selective genes, such as alkaline phosphatase (ALPL), occurs through activation of pre-established enhancers, i.e., regulatory regions bound by transcriptional regulators prior to osteogenic induction. Using mass spectrometry-based quantitative proteomics, we identified 324 proteins with lineage-specific association to putative ALPL enhancer sequences during early osteoblast and adipocyte differentiation. Barrier to autointegration protein 1 (BANF1), known to be involved in chromatin compression and mutated in the Nestor-Guillermo progeria syndrome, was identified as a factor binding ALPL enhancers in an osteogenesis-selective manner. Using ChIP-seq analysis, we show here that BANF1associates with both structural and regulatory elements of the chromatin landscape in stromal cells and that BANF1 bound regulatory elements and nearby genes show increased activity upon osteogenic differentiation. Modulating BANF1 protein levels, first, alters expression of genes with nearby BANF1 binding, and second, strongly correlates with WNT signaling, osteogenic differentiation and bone forming capacity of the cells. Finally, genetic data reveal that the BANF1 locus harbors human sequence variations that correlate changes in bone mineral density and BANF1 expression while expression data from human bone related biopsies link decreased BANF1 expression with aging and osteoporosis. In conclusion, we identified BANF1 as a strong pro-osteogenic factor that is necessary for the maintenance of a cellular and molecular signature of osteoblast activity and bone formation in vivo.
2023-07-01 | GSE227263 | GEO
Project description:Synergistic induction of blood-brain barrier properties
| PRJNA932784 | ENA
Project description:Human mesenchymal stromal cells (hMSCs) are able to differentiate into a wide variety of cell types, which makes them an interesting source for tissue engineering applications. On the other hand, these cells also secrete a broad panel of growth factors and cytokines that can exert trophic effects on surrounding tissues. In bone tissue engineering applications, the general assumption is that direct differentiation of hMSCs into osteoblasts accounts for newly observed bone formation in vivo. However, the secretion of bone-specific growth factors, but also pro-angiogenic factors, could also contribute to this process. We recently demonstrated that secretion of bone specific growth factors can be enhanced by treatment of hMSCs with the small molecule db-cAMP (cAMP) and here we investigate the biological activity of these secreted factors. We demonstrate that conditioned medium contains a variety of secreted growth factors, with differences between medium from basic-treated and cAMP-treated hMSCs. We show that conditioned medium from cAMP-treated hMSCs increases proliferation of various cell types and also induces osteogenic differentiation, whereas it has differential effects on migration. Microarray analysis on hMSCs exposed to conditioned medium confirmed upregulation of pathways involved in proliferation as well as osteogenic differentiation. Our data suggests that trophic factors secreted by hMSCs can be tuned for specific applications and that a good balance between differentiation on the one hand and secretion of bone trophic factors on the other, could potentially enhance bone formation for bone tissue engineering applications. For more information check: https://cbit.maastrichtuniversity.nl/
2018-10-06 | E-MTAB-7224 | biostudies-arrayexpress
Project description:Distinct properties and functions of CTCF revealed by a rapidly inducible degron system [PRO-Seq]
| PRJNA632002 | ENA
Project description:Blood–brain barrier (BBB) models derived from human stem cells are powerful tools to improve our understanding of cerebrovascular diseases and to facilitate drug development for the human brain. Yet providing stem cell–derived endothelial cells with the right signaling cues to acquire BBB characteristics while also retaining their vascular identity remains challenging. Here, we show that the simultaneous activation of cyclic AMP and Wnt/β-catenin signaling and inhibition of the TGF-β pathway in endothelial cells robustly induce BBB properties in vitro. To target this interaction, we present a small-molecule cocktail named cARLA, which synergistically enhances barrier tightness in a range of BBB models across species. Mechanistically, we reveal that the three pathways converge on Wnt/β-catenin signaling to mediate the effect of cARLA via the tight junction protein claudin-5. We demonstrate that cARLA shifts the gene expressional profile of human stem cell–derived endothelial cells toward the in vivo brain endothelial signature, with a higher glycocalyx density and efflux pump activity, lower rates of endocytosis, and a characteristic endothelial response to proinflammatory cytokines. Finally, we illustrate how cARLA can improve the predictive value of human BBB models regarding the brain penetration of drugs and targeted nanoparticles. Due to its synergistic effect, high reproducibility, and ease of use, cARLA has the potential to advance drug development for the human brain by improving BBB models across laboratories.
2024-04-18 | GSE224846 | GEO
Project description:Mitochondrial 3243A > G mutation confers pro-atherogenic and pro-inflammatory properties in MELAS iPS derived endothelial cells
| PRJNA524862 | ENA
Project description:Bone tissue engineering is considered the optimal solution for the repair of large bone defects. Previous studies by our team have demonstrated the effectiveness of a "bottom-up" microtissue engineering strategy using bone marrow mesenchymal stem cells (BMSCs) to improve the utilization efficiency of seed cells. However, this strategy requires the extraction of bone marrow, which is associated with significant trauma and difficulties in obtaining the cells. Adipose-derived mesenchymal stem cells (ADSCs), obtained from aspirated adipose tissue, offer a less invasive and more accessible alternative, but their osteogenic capacity is noticeably weaker, severely limiting their application as seed cells in bone tissue engineering repair.Cell-free fat extract (CEFFE) is a cell-free liquid component extracted from adipose tissue, which exhibits beneficial properties such as promoting proliferation, antioxidation, anti-apoptosis, and angiogenesis. In this study, during the preparation of ADSC-based osteogenic microtissues, we first discovered that CEFFE significantly enhanced the osteogenic activity of ADSCs. Furthermore, we observed the formation of dense osteogenic membranes as early as day 7 of osteogenic induction. When the microtissues based on CEFFE-treated ADSCs were implanted subcutaneously in nude mice, we found a significant enhancement in their osteogenic activity. Finally, to further investigate the mechanism underlying the enhancement of ADSC osteogenic differentiation by CEFFE, we performed transcriptomic analysis of CEFFE-treated ADSCs and validated the activation of the key PI3K-Akt pathway using Western blotting.In conclusion, this study presents a novel approach for the preparation of ADSC-based osteogenic microtissues using CEFFE and provides insights into the mechanisms underlying the enhancement of osteogenic activity. These findings hold significant implications for the field of bone tissue engineering and offer potential advancements in the clinical translation of ADSC-based therapies.
2023-08-09 | GSE235305 | GEO
Project description:During fundamental proteotranscriptomic analysis of human valve interstitial cells (VICs) osteogenic differentiation, we revealed ZBTB16 (PLZF) as one of the most upregulated proteins. Thus, to investigate its physiological role in VICs osteogenic differentiation we performed its overexpression by lentiviral transduction with subsequent proteomics analysis. Despite obvious PLZF overexpression and its reinforcing effect on osteogenic differentiation, we revealed surprisingly small amount of differentially expressed proteins that assumed to be the targets of PLZF.
2022-10-21 | PXD031572 | Pride
Project description:Hypoxia controls the glycobiological signature and related pro-tumorigenic properties of metastatic melanomas
| PRJNA780950 | ENA
Project description:Vascular calcification is common pathology various forms of which presented in the half of humans. Calcific aortic valve disease (CAVD) is one of the most dangerous forms of vascular calcification. Despite high mortality there is no target therapy against CAVD. Thus, we tested crenigacestat (LY3039478), inhibitor of Notch-signaling, and shRNA against RBPJk for inhibition of osteogenic differentiation of velve intersticial cells (VICs) in vitro. Both of them effectivelly enhibited osteogenic differentiation and we performed proteomics analysis do describe molecular mechanisms of their effect. Presented dataset contain results of shotgun proteomics analysis with ion mobility in TimsToF Pro instrument (in DDA PASEF mode) of VICs in classic osteogenic medium (OM) and OM supplemented with crenigacestat, DMSO or shCSL.
2022-10-04 | PXD029632 | Pride